Discovery of potent wall teichoic acid early stage inhibitors. Issue 16 (15th August 2016)

• Record Type: Journal Article
• Authors: Labroli, Marc A.; Caldwell, John P.; Yang, Christine; Lee, Sang Ho; Wang, Hao; Koseoglu, Sandra; Mann, Paul; Yang, Shu-Wei; Xiao, Jing; Garlisi, Charles G.; Tan, Christopher; Roemer, Terry; Su, Jing
• Is Part Of: Bioorganic & medicinal chemistry letters. Volume 26:Issue 16(2016)
• Page Start: 3999
• Page End: 4002
• Publication Date: 2016-08-15
• Subjects: Antibacterial -- Wall teichoic acid -- Antibiotic resistance -- MRSA; Bioorganic chemistry -- Periodicals; Pharmaceutical chemistry -- Periodicals; 572
• DOI: 10.1016/j.bmcl.2016.06.090
• Languages: English
• ISSNs: 0960-894X

Abstract

Graphical abstract: Herein we describe the optimization of a series of inhibitors termed tarocins which demonstrate by genetic and biochemical means inhibition of TarO, the first step in wall teichoic acid (WTA) biosynthesis. Tarocins demonstrate potent bactericidal synergy in combination with broad spectrum β-lactam antibiotics across diverse clinical isolates of methicillin-resistant Staphylococci . Abstract: The widespread emergence of methicillin-resistant Staphylococcus aureus (MRSA) has dramatically eroded the efficacy of current β-lactam antibiotics and created an urgent need for novel treatment options. Using an S. aureus phenotypic screening strategy, we have identified small molecule early stage wall teichoic acid (WTA) pathway-specific inhibitors predicted to be chemically synergistic with β-lactams. These previously disclosed inhibitors, termed tarocins, demonstrate by genetic and biochemical means inhibition of TarO, the first step in WTA biosynthesis. Tarocins demonstrate potent bactericidal synergy in combination with broad spectrum β-lactam antibiotics across diverse clinical isolates of methicillin-resistant Staphylococci . The synthesis and structure–activity relationships (SAR) of a tarocin series will be detailed. Tarocins and other WTA inhibitors may provide a rational strategy to develop Gram-positive bactericidal β-lactam combination agents active against methicillin-resistant Staphylococci .